Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer
February 25, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
February 24, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
February 06, 2020 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 20, 2019 16:01 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
December 17, 2019 22:26 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
December 17, 2019 16:38 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Scientific Advisory Board
December 05, 2019 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results
November 13, 2019 09:15 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Wash., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Additions to Management Team
September 19, 2019 08:00 ET
|
Neoleukin Therapeutics, Inc.
Leslie Aberman, Vice President, Legal Affairs and Intellectual PropertySamantha Willing, Vice President, People SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc....